Nemera organized an expert review on the present and future of inhalation products.
“Connectivity in every new inhalation device?” This topic was one of those discussed with different inhalation experts – Manfred Keller, Pascal Cavaillon and Henry Chrystyn – during a round table organized by Nemera in Paris to review the advantages and limitations of inhalation devices.
Inhalation treatments, composed of solid particles or liquid droplets are generally administered to the lungs via inhalation limiting side effects versus other administration modes (oral, injectable etc…). Their efficacy depends on the drug used, the particle/droplet physical and chemical properties, as well as the patient’s breathing pattern, lung anatomy and physiology.
The inhaler device generating the particles/droplet is the direct interface with the patient and it can influence patient’s adherence and treatment efficacy. Four categories of inhalers exist.
Dry powder inhalers (DPIs) are portable and deliver small or large doses. They are passive devices requiring the patient to inhale with a high inspiratory flow rate.
Pressurized Metered dose inhalers (pMDIs) are portable and deliver small doses of solution or suspension. Their efficacy is limited by a strong need for coordination and an important deposition of aerosol in the mouth.
Soft mist inhalers (SMI) are portable and deliver a small dose of solution. In comparison with pMDI, they reduce mouth deposition and generate a “mist of droplets” lasting longer than the pMDI aerosol.
Nebulizers are medical devices delivering high dose of solution. In this category, mesh nebulizers are becoming smaller and more portable.
The doctor’s choice of an inhaler for a patient is mainly done according patient’s preference after having tested different devices. This device selection is key in a treatment as some studies prove that the more a patient likes his inhaler the more adherent he will be. This round table raised the conclusion that the addition of electronic and connectivity on inhalers may also improve the adherence of patients and consequently, treatment efficacy in the future.
Respiratory diseases still impact the everyday life of many people. The latest estimates from WHO mentions a total of 481 million of person suffering globally from Asthma and Chronic Obstructive Pulmonary Disease (COPD). Treatments are generally administered to the lungs via inhalation limiting side effects versus other administration modes.
Nemera is a world leader in the design, development and manufacturing of drug delivery devices for the pharmaceutical, biotechnology & generics industries.
Nemera’s services and products cover several key delivery routes: Inhalation (pMDI, DPIs), Nasal/Buccal/Auricular (spray pumps, actuators, valves, etc.), Ophthalmic (preservative-free multidose eyedroppers), Dermal /Transdermal (airless & atmospheric dispensers), and Parenteral (autoinjectors, pens, and safety devices).
Nemera always puts patients first, providing the most comprehensive range of devices in the industry, including off-the-shelf innovative systems, customized design development and customer IP manufacturing.